menu
    • menu
    [{"orgOrder":0,"company":"Nuance Pharma","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Series D Financing","leadProduct":"Polysaccharide iron complex","moa":"CIAO2B","graph1":"Hematology","graph2":"Approved","graph3":"Nuance Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Nuance Pharma \/ RTW Investments","highestDevelopmentStatusID":"12","companyTruncated":"Nuance Pharma \/ RTW Investments"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Antibe Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Nuance Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Nuance Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Nuance Pharma \/ Nuance Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Verona Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Ensifentrine","moa":"PDE3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0.22,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.22,"dosageForm":"Inhalation","sponsorNew":"Nuance Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Nuance Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Aerogen","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"AP-002","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nuance Pharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20999999999999999,"dosageForm":"Inhalation","sponsorNew":"Nuance Pharma \/ Aerogen","highestDevelopmentStatusID":"8","companyTruncated":"Nuance Pharma \/ Aerogen"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Neumentum","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nuance Pharma \/ Neumentum","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Neumentum"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3\/PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Nuance Pharma \/ Verona Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Verona Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"PDE3\/PDE4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Nuance Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Nuance Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AM-301","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nuance Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Nuance Pharma \/ Nuance Pharma"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Bentonite","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nuance Pharma \/ DKSH","highestDevelopmentStatusID":"12","companyTruncated":"Nuance Pharma \/ DKSH"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Nuance Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ensifentrine","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Nuance Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nuance Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nuance Pharma","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BERMUDA","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bentonite","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Nuance Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Nuance Pharma \/ Nuance Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Nuance Pharma \/ Nuance Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Nuance Pharma

    Menu

    Nuance Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bentonite

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Altamira Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Altamira Expands Bentrio Deal with Nuance Pharma For Asia Distribution

                            Details : Altamira will extend the territory covered by their exclusive license and distribution agreement by Nuance for Bentrio (bentonite) nasal spray by several countries across South East and East Asia.

                            Brand Name : Bentrio

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 16, 2024

                            Lead Product(s) : Bentonite

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Altamira Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nuance Pharma Announces Dosing of First Patient in ENHANCE China Phase 3 Trial for COPD

                            Details : RPL554 (ensifentrine) is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.

                            Brand Name : RPL554

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 10, 2023

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pul...

                            Details : Ensifentrine is a selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and NSAID activities in one compound. This activity has the potential to provide anti-inflammatory benefits for those with COPD.

                            Brand Name : RPL554

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 06, 2023

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AM-301

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Altamira Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma

                            Details : AM-301, marketed as Bentrio™, is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa.

                            Brand Name : Bentrio

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : AM-301

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Altamira Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bentonite,Mono Propylene Glycol,Citric Acid

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : DKSH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Nuance Pharma Announces Partnership With DKSH To Launch Bentrio™ Nasal Spray In Hong Kong And Macau

                            Details : Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.

                            Brand Name : Bentrio

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 28, 2022

                            Lead Product(s) : Bentonite,Mono Propylene Glycol,Citric Acid

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : DKSH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Verona Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nuance Pharma Receives Clearance to Begin Pivotal Clinical Trials With Ensifentrine for COPD in China

                            Details : RPL554 (ensifentrine) met primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function,significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial.

                            Brand Name : RPL554

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 19, 2022

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Verona Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Verona Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in Chin...

                            Details : Ensifentrine (RPL554) is an investigational, first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") that combines bronchodilator and anti-inflammatory activities in one compound.

                            Brand Name : RPL554

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Verona Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketorolac Trometamol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Neumentum

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nuance Pharma Announces the Completion of Dosing for All NTM-001 Phase 1 Clinical Study Participants in HKU Cl...

                            Details : Ketorolac (NTM-001) is a novel, alcohol-free formulation of ketorolac in a convenient, ready-to-use, pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia.

                            Brand Name : NTM-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 26, 2022

                            Lead Product(s) : Ketorolac Trometamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Neumentum

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Aerogen

                            Deal Size : $212.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distres...

                            Details : The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in ...

                            Brand Name : AeroFact

                            Molecule Type : Small molecule

                            Upfront Cash : $20.0 million

                            December 22, 2021

                            Lead Product(s) : AP-002

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Aerogen

                            Deal Size : $212.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Nuance Pharma

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Recipient : Verona Pharma

                            Deal Size : $219.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ens...

                            Details : Ensifentrine (RPL554) is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3” and “PDE4”). Verona Pharma has granted Nuance Pharma the exclusive rights to develop and commercialize ensifentr...

                            Brand Name : RPL554

                            Molecule Type : Small molecule

                            Upfront Cash : $40.0 million

                            June 10, 2021

                            Lead Product(s) : Ensifentrine

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Recipient : Verona Pharma

                            Deal Size : $219.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth